Zobrazeno 1 - 10
of 66 393
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu
Autor:
Foteinos-Ioannis Dimitrakopoulos, Kyriaki Papadopoulou, Dimitrios Pectasides, Anna Batistatou, Kitty Pavlakis, George Fountzilas, Helen P. Kourea, Sofia Chrisafi, George Pentheroudakis, Vassiliki Kotoula, Pavlos Papakostas, Eleni Galani, Eleni Res, Dimitrios Bafaloukos, Angelos Koutras, Georgia-Angeliki Koliou, Mattheos Bobos, Kyriakos Chatzopoulos, Anthoula Asimaki-Vlachopoulou
Publikováno v:
Cancer Research and Treatment. 54:1053-1064
Purpose Angiogenesis is a crucial phenomenon in the development and progression of breast cancer (BC), but the clinical significance of angiogenesis-related proteins in metastatic BC remains unknown. This study investigates the prognostic value of va
Autor:
Diana Xochiquetzal Robledo-Cadena, Marco Antonio García-Amezcua, Javier Alejandro Belmont-Díaz, Rafael Moreno-Sánchez, Alhelí Adán-Ladrón de Guevara, Silvia Cecilia Pacheco-Velázquez, Juan Carlos Gallardo-Pérez, Sara Rodríguez-Enríquez, Jorge Luis Vargas-Navarro
Publikováno v:
Current Medicinal Chemistry. 29:2719-2735
Background: The major hurdles for successful cancer treatment are drug resistance and invasiveness developed by breast cancer stem cells (BCSC). Objective: As these two processes are highly energy-dependent, the identification of the main ATP supplie
Autor:
Qin Zhou, Xiaohua Liu, Cuiling Qi, Jinlian Li, Lijing Wang, Qianqian Zhang, Lingyun Zheng, Jinghua Cao, Shuting Zheng, Guanquan Mao
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1735-1741
Background: Breast cancer is one of the most common cancers worldwide among women, and angiogenesis has an important effect on its growth and metastasis. Glipizide, which is a widely used drug for type 2 diabetes mellitus, has been reported to inhibi
Publikováno v:
Medicinal Chemistry. 18:589-601
Background: Breast cancer is the leading cause of cancer death in women. The current methods of chemotherapy for breast cancer generally have strong adverse reactions and drug resistance. Therefore, the discovery of novel anti-breast cancer lead comp
Autor:
Afnan K. AlHiary, Lina A. Dahabiyeh, Anas M. Abdel Rahman, James W. Dennis, Judy Pawling, Dana D. Shalabi, Bushra M. Akileh, Sanaa K. Bardaweel
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1611-1621
Background: Chronic inflammation plays a crucial role in the initiation, promotion, and invasion of tumors, and thus the antiproliferative effects of numerous anti-inflammatory drugs have been frequently reported in the literature. Upregulation of th
Autor:
Thorsten Lehr, Hannah Britz, Clinton F. Stewart, Daniel Moj, Walter E. Haefeli, Gerlinde Egerer, Jürgen Burhenne
This study aimed at recommending pediatric dosages of the histone deacetylase (HDAC) inhibitor vorinostat and potentially more effective adult dosing regimens than the approved standard dosing regimen of 400 mg/day, using a comprehensive physiologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b42701510c1983fe755fd57a7800a87